Skip to content
OpenCapital
Get started

Perspective Therapeutics CATX Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$28.83M-39.4%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$52.54M+32.3%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$176.35M+51.7%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$500.29M-46.8%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%—

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0×0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's cash & equivalents?
Perspective Therapeutics (CATX) reported cash & equivalents of $53.97M in Q1 2026.
How has Perspective Therapeutics's cash & equivalents changed year-over-year?
Perspective Therapeutics's cash & equivalents increased by 21.5% year-over-year, from $44.41M to $53.97M.
What is the long-term trend for Perspective Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Perspective Therapeutics's cash & equivalents has grown at a 26.2% compound annual growth rate (CAGR), from $9.59M to $30.63M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.